{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:04:03Z","timestamp":1773677043652,"version":"3.50.1"},"reference-count":22,"publisher":"Texas Heart Institute Journal","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>We compared outcomes of percutaneous coronary intervention patients who received biodegradable-polymer biolimus-eluting stents with those who received durable-polymer everolimus-eluting stents.<\/jats:p>\n        <jats:p>At Tehran Heart Center, we performed a retrospective analysis of the data from January 2007 through December 2011 on 3,270 consecutive patients with coronary artery disease who underwent percutaneous coronary intervention with the biodegradable-polymer biolimus-eluting stent or the durable-polymer everolimus-eluting stent. We excluded patients with histories of coronary artery bypass grafting or percutaneous coronary intervention, acute ST-segment-elevation myocardial infarction, or the implantation of 2 different stent types. Patients were monitored for 12 months. The primary endpoint was a major adverse cardiac event, defined as a composite of death, nonfatal myocardial infarction, and target-vessel and target-lesion revascularization.<\/jats:p>\n        <jats:p>Durable-polymer everolimus-eluting stents were implanted in 2,648 (81%) and biodegradable-polymer biolimus-eluting stents in 622 (19%) of the study population. There was no significant difference between the 2 groups (2.7% vs 2.7%; <jats:italic>P<\/jats:italic>=0.984) in the incidence of major adverse cardiac events. The cumulative adjusted probability of major adverse cardiac events in the biodegradable-polymer biolimus-eluting stent group did not differ from that of such events in the durable-polymer everolimus-eluting stent group (hazard ratio=0.768; 95% confidence interval, 0.421\u20131.44; <jats:italic>P<\/jats:italic>=0.388).<\/jats:p>\n        <jats:p>We conclude that in our patients the biodegradable-polymer biolimus-eluting stent was as effective and safe, during the 12-month follow-up period, as was the durable-polymer everolimus-eluting stent.<\/jats:p>","DOI":"10.14503\/thij-14-4997","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T22:00:25Z","timestamp":1459893625000},"page":"126-130","source":"Crossref","is-referenced-by-count":5,"title":["Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study"],"prefix":"10.14503","volume":"43","author":[{"given":"Ehsan","family":"Parsa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Saroukhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshteh","family":"Majlessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Poorhosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Lofti-Tokaldany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojtaba","family":"Salarifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebrahim","family":"Nematipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Alidoosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Aghajani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Amirzadegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ebrahim","family":"Kassaian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5628","reference":[{"issue":"2","key":"i0730-2347-43-2-126-b1","series-title":"Vasc Health Risk Manag","first-page":"191","article-title":"Sirolimus-eluting coronary stents: a review","volume":"3","year":"2007","unstructured":"Abizaid\n              A.\n            \n          \n          Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag2007;3(2):191\u2013201."},{"issue":"3","key":"i0730-2347-43-2-126-b2","series-title":"Am J Cardiovasc Drugs","first-page":"211","article-title":"The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease","volume":"3","year":"2003","unstructured":"McKeage\n              K, \n            \n              Murdoch\n              D, \n            \n              Goa\n              KL.\n            \n          \n          The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. Am J Cardiovasc Drugs2003;3(3):211\u201330."},{"issue":"3","key":"i0730-2347-43-2-126-b3","series-title":"J Tehran Heart Cent","first-page":"138","article-title":"One-year clinical outcomes of ultra long Apollo polymer-based paclitaxel-eluting stents in patients with complex, long coronary artery lesions","volume":"6","year":"2011","unstructured":"Salarifar\n              M, \n            \n              Kassaian\n              SE, \n            \n              Alidoosti\n              M, \n            \n              Haji-Zeinali\n              AM, \n            \n              Poorhosseini\n              HR, \n            \n              Nematipour\n              E, \n          \n          et al. One-year clinical outcomes of ultra long Apollo polymer-based paclitaxel-eluting stents in patients with complex, long coronary artery lesions. J Tehran Heart Cent2011;6(3):138\u201342."},{"issue":"5","key":"i0730-2347-43-2-126-b4","series-title":"Tex Heart Inst J","first-page":"477","article-title":"Selective versus exclusive use of drug-eluting stents in treating multivessel coronary artery disease: a real-world cohort study","volume":"41","year":"2014","unstructured":"Karbassi\n              A, \n            \n              Kassaian\n              SE, \n            \n              Poorhosseini\n              H, \n            \n              Salarifar\n              M, \n            \n              Jalali\n              A, \n            \n              Nematipour\n              E, \n          \n          et al. Selective versus exclusive use of drug-eluting stents in treating multivessel coronary artery disease: a real-world cohort study. Tex Heart Inst J2014;41(5):477\u201383."},{"key":"i0730-2347-43-2-126-b5","series-title":"Thrombosis","first-page":"608593","article-title":"Pathologic etiologies of late and very late stent thrombosis following first-generation drug-eluting stent placement","volume":"2012","year":"2012","unstructured":"Otsuka\n              F, \n            \n              Nakano\n              M, \n            \n              Ladich\n              E, \n            \n              Kolodgie\n              FD, \n            \n              Virmani\n              R.\n            \n          \n          Pathologic etiologies of late and very late stent thrombosis following first-generation drug-eluting stent placement. Thrombosis2012;2012:608593."},{"issue":"3","key":"i0730-2347-43-2-126-b6","series-title":"Herz","first-page":"190","article-title":"Second- and third-generation drug-eluting coronary stents: progress and safety","volume":"36","year":"2011","unstructured":"Akin\n              I, \n            \n              Schneider\n              H, \n            \n              Ince\n              H, \n            \n              Kische\n              S, \n            \n              Rehders\n              TC, \n            \n              Chatterjee\n              T, \n            \n              Nienaber\n              CA.\n            \n          \n          Second- and third-generation drug-eluting coronary stents: progress and safety. Herz2011;36(3):190\u20136."},{"issue":"9","key":"i0730-2347-43-2-126-b7","series-title":"JACC Cardiovasc Interv","first-page":"914","article-title":"Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions)","volume":"6","year":"2013","unstructured":"Dangas\n              GD, \n            \n              Serruys\n              PW, \n            \n              Kereiakes\n              DJ, \n            \n              Hermiller\n              J, \n            \n              Rizvi\n              A, \n            \n              Newman\n              W, \n          \n          et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv2013;6(9):914\u201322."},{"issue":"1","key":"i0730-2347-43-2-126-b8","series-title":"J Am Coll Cardiol","first-page":"19","article-title":"Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial","volume":"58","year":"2011","unstructured":"Stone\n              GW, \n            \n              Rizvi\n              A, \n            \n              Sudhir\n              K, \n            \n              Newman\n              W, \n            \n              Applegate\n              RJ, \n            \n              Cannon\n              LA, \n          \n          et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol2011;58(1):19\u201325."},{"issue":"9710","key":"i0730-2347-43-2-126-b9","series-title":"Lancet","first-page":"201","article-title":"Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial","volume":"375","year":"2010","unstructured":"Kedhi\n              E, \n            \n              Joesoef\n              KS, \n            \n              McFadden\n              E, \n            \n              Wassing\n              J, \n            \n              van Mieghem\n              C, \n            \n              Goedhart\n              D, \n            \n              Smits\n              PC.\n            \n          \n          Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet2010;375(9710):201\u20139."},{"issue":"4","key":"i0730-2347-43-2-126-b10","series-title":"Circ Cardiovasc Interv","first-page":"384","article-title":"New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems","volume":"3","year":"2010","unstructured":"Abizaid\n              A, \n            \n              Costa\n              JR\n              Jr.\n            \n          \n          New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv2010;3(4):384\u201393."},{"issue":"4","key":"i0730-2347-43-2-126-b11","series-title":"J Interv Cardiol","first-page":"399","article-title":"Comparison of the safety and efficacy of biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents: propensity score-matched analysis","volume":"27","year":"2014","unstructured":"Lee\n              JH, \n            \n              Lee\n              JW, \n            \n              Youn\n              YJ, \n            \n              Ahn\n              MS, \n            \n              Ahn\n              SG, \n            \n              Kim\n              JY, \n          \n          et al. Comparison of the safety and efficacy of biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents: propensity score-matched analysis. J Interv Cardiol2014;27(4):399\u2013407."},{"issue":"3","key":"i0730-2347-43-2-126-b12","series-title":"EuroIntervention","first-page":"336","article-title":"Long-term comparison of everolimus-eluting and biolimus-eluting stents","volume":"9","year":"2013","unstructured":"Puricel\n              S, \n            \n              Oberhansli\n              M, \n            \n              Guntern\n              P, \n            \n              Lehmann\n              S, \n            \n              Goy\n              JJ, \n            \n              Arroyo\n              D, \n          \n          et al. Long-term comparison of everolimus-eluting and biolimus-eluting stents. EuroIntervention2013;9(3):336\u201344."},{"issue":"4","key":"i0730-2347-43-2-126-b13","series-title":"EuroIntervention","first-page":"505","article-title":"Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review","volume":"7","year":"2011","unstructured":"Ahmed\n              TA, \n            \n              Bergheanu\n              SC, \n            \n              Stijnen\n              T, \n            \n              Plevier\n              JW, \n            \n              Quax\n              PH, \n            \n              Jukema\n              JW.\n            \n          \n          Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. EuroIntervention2011;7(4):505\u201316."},{"issue":"1","key":"i0730-2347-43-2-126-b14","series-title":"EuroIntervention","first-page":"109","article-title":"Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study","volume":"8","year":"2012","unstructured":"Danzi\n              GB, \n            \n              Chevalier\n              B, \n            \n              Urban\n              P, \n            \n              Fath-Ordoubadi\n              F, \n            \n              Carrie\n              D, \n            \n              Wiemer\n              M, \n          \n          et al. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. EuroIntervention2012;8 (1):109\u201316."},{"issue":"2","key":"i0730-2347-43-2-126-b15","series-title":"EuroIntervention","first-page":"233","article-title":"The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer","volume":"6","year":"2010","unstructured":"Garg\n              S, \n            \n              Sarno\n              G, \n            \n              Serruys\n              PW, \n            \n              de Vries\n              T, \n            \n              Buszman\n              P, \n            \n              Linke\n              A, \n          \n          et al. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention2010; 6(2):233\u20139."},{"issue":"1","key":"i0730-2347-43-2-126-b16","series-title":"Circulation","first-page":"74","article-title":"Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial","volume":"131","year":"2015","unstructured":"Kaiser\n              C, \n            \n              Galatius\n              S, \n            \n              Jeger\n              R, \n            \n              Gilgen\n              N, \n            \n              Skov Jensen\n              J, \n            \n              Naber\n              C, \n          \n          et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation2015;131(1):74\u201381."},{"issue":"4","key":"i0730-2347-43-2-126-b17","series-title":"Eur J Prev Cardiol","first-page":"411","article-title":"Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients","volume":"21","year":"2014","unstructured":"Lupi\n              A, \n            \n              Rognoni\n              A, \n            \n              Secco\n              GG, \n            \n              Lazzero\n              M, \n            \n              Nardi\n              F, \n            \n              Fattori\n              R, \n          \n          et al. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. Eur J Prev Cardiol2014;21(4):411\u201324."},{"issue":"9824","key":"i0730-2347-43-2-126-b18","series-title":"Lancet","first-page":"1368","article-title":"Stent thrombosis: has the fire-storm been extinguished?","volume":"379","year":"2012","unstructured":"Ormiston\n              JA, \n            \n              Webster\n              MW.\n            \n          \n          Stent thrombosis: has the fire-storm been extinguished?\n          Lancet\n          2012;379(9824):1368\u20139."},{"issue":"9644","key":"i0730-2347-43-2-126-b19","series-title":"Lancet","first-page":"1163","article-title":"Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial","volume":"372","year":"2008","unstructured":"Windecker\n              S, \n            \n              Serruys\n              PW, \n            \n              Wandel\n              S, \n            \n              Buszman\n              P, \n            \n              Trznadel\n              S, \n            \n              Linke\n              A, \n          \n          et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet2008;372(9644):1163\u201373."},{"key":"i0730-2347-43-2-126-b20","series-title":"Clin Med Insights Cardiol","first-page":"115","article-title":"Second generation drug-eluting stents: a review of the everolimus-eluting platform","volume":"7","year":"2013","unstructured":"Whitbeck\n              MG, \n            \n              Applegate\n              RJ.\n            \n          \n          Second generation drug-eluting stents: a review of the everolimus-eluting platform. Clin Med Insights Cardiol2013;7:115\u201326."},{"issue":"9867","key":"i0730-2347-43-2-126-b21","series-title":"Lancet","first-page":"651","article-title":"Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial","volume":"381","year":"2013","unstructured":"Smits\n              PC, \n            \n              Hofma\n              S, \n            \n              Togni\n              M, \n            \n              Vazquez\n              N, \n            \n              Valdes\n              M, \n            \n              Voudris\n              V, \n          \n          et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet2013;381(9867):651\u201360."},{"issue":"3","key":"i0730-2347-43-2-126-b22","series-title":"Int J Cardiovasc Imaging","first-page":"495","article-title":"Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography","volume":"30","year":"2014","unstructured":"Tada\n              T, \n            \n              Kastrati\n              A, \n            \n              Byrne\n              RA, \n            \n              Schuster\n              T, \n            \n              Cuni\n              R, \n            \n              King\n              LA, \n          \n          et al. Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. Int J Cardiovasc Imaging2014;30(3):495\u2013504."}],"container-title":["Texas Heart Institute Journal"],"original-title":[],"link":[{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/43\/2\/article-p126.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/thij\/article-pdf\/43\/2\/126\/1969570\/thij-14-4997.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/43\/2\/article-p126.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/43\/2\/article-p126.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:34:01Z","timestamp":1730993641000},"score":1,"resource":{"primary":{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/43\/2\/article-p126.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":22,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.14503\/thij-14-4997","relation":{},"ISSN":["0730-2347","1526-6702"],"issn-type":[{"value":"0730-2347","type":"print"},{"value":"1526-6702","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}